This issue will mark the last issue for me as Editor of PTE. It's time for me to move on to pastures new and to say my goodbyes.
This issue will mark the last issue for me as Editor of PTE. It's time for me to move on to pastures new and to say my goodbyes. But before I do, I would like to say what a pleasure it has been for me to serve as Editor of Pharmaceutical TechnologyEurope. I have witnessed some very exciting but also incredibly testing times within the industry during my time as Editor, but I am in great admiration of the work that you do and some of the innovative ways that companies have adapted to withstand the impact of the significant market changes — from economic uncertainties through to patent expirations, the growth of biologics, and strong competition from emerging countries, to name just a few of the challenges. I can, however, guarantee that PTE will continue to keep you updated on all of the latest issues, developments and innovations within your market. We have an incredibly talented team here at Pharmaceutical Technology and I am confident that they will serve you to the best of their ability. I would now like to take this opportunity to thank you so much for your invaluable support of PTE and to introduce you to our very talented new Editor of PTE, Rich Whitworth.
Fedra
Many thanks and very best wishes,
Fedra Pavlou, Editor-in-Chief
Let me begin by thanking Fedra for all of her hard work over the past few years, and for handing over a very healthy PTE. I am sure you will all join me in wishing her the very best for the future.
Rich
I am excited to be joining the editorial team at PTE so early in the new year and very much looking forward to having real contact with some of you wherever possible. Over the coming months, I plan to continue to nurture our active online community of readers and contributors, which offers such an important extra dimension to PTE and facilitates rapid exchange of new ideas, concerns, and hopes for the future. This online bond between reader, writer—and the editorial team—enables us to guide PTE in directions of your choosing, responding quickly to trends and issues you consider most important in this dynamic industry.
Please join us on LinkedIn (www.pharmtech.com/linkedin), follow us on Twitter (www.pharmtech.com/follow), and get involved!
Many thanks in advance for your continued support,
Rich Whitworth, Editor
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.